Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

NCT07265947 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Low Grade Upper Tract Urothelial Carcinoma

Interventions

DRUG: Dabogratinib (TYRA-300) 60mg
DRUG: Dabogratinib (TYRA-300) 80mg
DRUG: Dabogratinib (TYRA-300) TBD

Sponsor

Tyra Biosciences, Inc